Example: barber

Prostate Cancer - tri-kobe.org

2016 3 05/26/2016 2016 National Comprehensive Cancer Network, Inc. NCCN NCCN Guidelines Version NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) NCCN NCCN Guidelines for Patients 2016 3 2016 3 05/26/2016 2016 National Comprehensive Cancer Network, Inc. NCCN NCCN Guidelines Version * James L. Mohler, MD/Chair Roswell Park Cancer Institute * Andrew J. Armstrong, MD Duke Cancer Institute Robert R. Bahnson, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Anthony Victor D Amico, MD, PhD Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center Brian J.

2016年第3版 05/26/2016 著作権 © 2016 National Comprehensive Cancer Network, Inc. 無断転載を禁止する。NCCN®の明示の書面による許諾なく、本ガイドラインおよびここに含まれるイラストを複製することは、いかなる形態においても禁じられている。

Tags:

  Kobe, Tri kobe

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of Prostate Cancer - tri-kobe.org

1 2016 3 05/26/2016 2016 National Comprehensive Cancer Network, Inc. NCCN NCCN Guidelines Version NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) NCCN NCCN Guidelines for Patients 2016 3 2016 3 05/26/2016 2016 National Comprehensive Cancer Network, Inc. NCCN NCCN Guidelines Version * James L. Mohler, MD/Chair Roswell Park Cancer Institute * Andrew J. Armstrong, MD Duke Cancer Institute Robert R. Bahnson, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Anthony Victor D Amico, MD, PhD Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center Brian J.

2 Davis, MD, PhD Mayo Clinic Cancer Center James A. Eastham, MD Memorial Sloan Kettering Cancer Center Charles A. Enke, MD Fred & Pamela Buffett Cancer Center Thomas A. Farrington Prostate Health Education Network (PHEN) * Celestia S. Higano, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance Eric Mark Horwitz, MD Fox Chase Cancer Center Michael Hurwitz, MD, PhD Yale Cancer Center/Smilow Cancer Hospital Christopher J. Kane, MD UC San Diego Moores Cancer Center Mark H. Kawachi, MD City of Hope Comprehensive Cancer Center Michael Kuettel, MD, MBA, PhD Roswell Park Cancer Institute Richard J. Lee, MD, PhD Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center Joshua J. Meeks, MD, PhD Robert H. Lurie Comprehensive Cancer Center of Northwestern University David F. Penson, MD, MPH Vanderbilt-Ingram Cancer Center Elizabeth R.

3 Plimack, MD, MS Fox Chase Cancer Center Julio M. Pow-Sang, MD Moffitt Cancer Center David Raben, MD University of Colorado Cancer Center Sylvia Richey, MD St. Jude Children s Research Hospital/ University of Tennessee Health Science Center Mack Roach, III, MD UCSF Helen Diller Family Comprehensive Cancer Center Stan Rosenfeld University of California San Francisco Patient Services Committee Chair * Edward Schaeffer, MD, PhD Robert H. Lurie Comprehensive Cancer Center of Northwestern University * Ted A. Skolarus, MD University of Michigan Comprehensive Cancer Center Eric J. Small, MD UCSF Helen Diller Family Comprehensive Cancer Center Guru Sonpavde, MD University of Alabama at Birmingham Comprehensive Cancer Center Sandy Srinivas, MD Stanford Cancer Institute Seth A. Strope, MD, MPH Siteman Cancer Center at Barnes- Jewish Hospital and Washington University School of Medicine Jonathan Tward, MD, PhD Huntsman Cancer Institute at the University of Utah NCCN Deborah Freedman-Cass, PhD Dorothy A.

4 Shead, MS / / / * NCCN 2016 3 05/26/2016 2016 National Comprehensive Cancer Network, Inc. NCCN NCCN Guidelines Version NCCN PROS-1 PROS-2 PROS-3 PROS-4 PROS-5 PROS-6 PROS-7 PROS-8 PROS-9 M0 CRPC PROS-10 M1 CRPC PROS-11 M1 CRPC PROS-12 M1 CRPC PROS-13 PROS-A PROS-B Active surveillance PROS-C PROS-D) PROS-E PROS-F PROS-G ST-1 NCCN NCCN National Comprehensive Cancer Network NCCN NCCN National Comprehensive Cancer Network NCCN NCCN 2016 NCCN NCCN NCCN 2A NCCN NCCN Guidelines Version 2016 3 05/26/2016 2016 National Comprehensive Cancer Network, Inc.

5 NCCN 2A NCCN NCCN 2016 2 2016 3 PROS-7 X CT/MRI TRUS CT/MRI / TRUS u X / CT MRI C-11 PET PROS-B PROS-7 -8 -9 -10 -11 PROS-8 X NCCN 2016 1 2016 2 PROS-2 -3 Active surveillance PSA / mpMRI NCCN 2015 1 2016 1 PROS-1 b NCCN d PROS-5 PROS-2 -3 Active surveillance m PROS-4 3 3 4 7 50 NCCN 1 active surveillance o active surveillance 10 1 PROS-5 EBRT ADT 2 3 3 6 T N1 M0 T N M1 EBRT ADT 1 ADT UPDATES-1 NCCN Guidelines Version 2016 3 05/26/2016 2016 National Comprehensive Cancer Network, Inc.

6 NCCN 2A NCCN UPDATES-2 EBRT PROS-7 CT/MRI TRUS PSA ADT PROS-8 TRUS RP PLND TRUS MR MRI PROS-9 M0 low volume M1 M1 high volume M0 M1 M0 M1 ADT PROS-F M1 75mg/m2 6 v low volume ADT / PROS-10 CRPC M0 CRPC DES DES 1mg/ 50ng/dL PROS-11 CRPC M1 CRPC 50ng/dL 1 PROS-10 DES DES DES 1mg/ 50ng/dL c PROS-12 PROS-13 CRPC M1 CRPC 223 1

7 2 1 PROS-A WHO Life Table by Country PROS-B (2 of 3) 18F-NaF PET III 18F-NaF PET PET 99 NCCN 2015 1 2016 1 NCCN Guidelines Version 2016 3 05/26/2016 2016 National Comprehensive Cancer Network, Inc. NCCN 2A NCCN PROS-B (3 of 3) RP PSA 2 RT PSA DRE MRI MRI/US fusion high grade 7 PROS-C (1 of 2) 3 3 4 7 50 NCCN 1 active surveillance Zumsteg Z, Spratt D, Pei I, et al.

8 A new risk classification system for therapeutic decision making with intermediate risk Prostate Cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64:895;2013. MRI/US fusion high grade 7 MRI PSA PROS-C (2 of 2) Active surveillance active surveillance 2/3 Active surveillance 2 1/3 PROS-D (1 of 2) 2 3 / / ADT 1 / IPSS TRUS ADT ADT ADT ADT PROS-D (2 of 2) RT 2 PSA PSADT PROS-F (2 of 4) ADT 2 3 ADT ADT PROS-F (3 of 4) CRPC M0 CRPC CRPC M1 CRPC PROS-G (2 of 2)

9 2 UPDATES-3 NCCN 2015 1 2016 1 NCCN Guidelines Version 2016 3 05/26/2016 2016 National Comprehensive Cancer Network, Inc. NCCN 2A NCCN c e T1c 6 PSA 10ng/mL 3 50 PSA density d a 5 PROS-2 e T2b T2c 7 PSA 10 20ng/mL DRE PSA primary secondary T1 PSA 20ng/mL T2 PSA 10ng/mL 8 T3 T4 PROS-4 CT MRI T3 T4 T1 T2 10 a 5 b PROS-5 a PROS-A b NCCN

10 C PROS-B d 5 ADT RT PROS-5 T3 T4 8 10 e 1 PROS-1 T3b T4 5 4 8 10 T N1 T N M1 PROS-3 T1 T2a 6 PSA 10ng/mL e T3a 8 10 PSA 20ng/mL NCCN Guidelines Version 2016 3 05/26/2016 2016 National Comprehensive Cancer Network, Inc. NCCN 2A NCCN a Active surveillance g 6 PSA 12 DRE 12 PSA / mpMRI 20 f EBRT h j EBRT h k RP i PLND 2 PROS-6 T1c 6 PSA 10ng/mL 3 50 PS